THE MARKET IS RIPE FOR AN OFFERING THAT ENABLES A POWERFUL RIPPLE EFFECT OF BENEFIT.
Sen-Jam Pharmaceutical’s mission is to create value by finding novel pharmaceutical solutions for large, unmet needs while forging global sales, distribution, and licensing agreements.
Sen-Jam’s Exulta™ portfolio is based on opioid free pain relief with GI protection for extended use.
Sen-Jam’s fixed dose combination products (patents pending) stabilize the release of histamines and prostaglandins while regulating pro-inflammatory cytokines, enabling Exulta™ to be used for numerous new indications.
Opioid induced hyperalgesia, tolerance and dependence may be mitigated by modulating glial cells. Exulta™ (006-007), a Peroxisome Proliferator Activated Receptor–γ (PPAR-γ) agonist, can modulate glial cell activity, with the potential to attenuate opioid induced detrimental side effects.